PYC.AX Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 geg. 2024 @ 08:16):

PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of drug solutions in the areas of ribonucleic acid therapeutics in Australia...

Stats
Dzisiejszy wolumen	6.90M
Średni wolumen	1.85M
Kapitalizacja rynkowa	513.27M
EPS	$0 ( 2024-02-25 )
Następna data zysków	( $0 ) 2024-07-23
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-11.00
ATR14	$0.00100 (0.91%)

Wolumen Korelacja

Długi: -0.14 (neutral)

Krótki: -0.51 (weak negative)

Signal:(43.418) Neutral

PYC Therapeutics Ltd Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

PYC Therapeutics Ltd Korelacja - Waluta/Towar

0.45
( neutral )

-0.44
( neutral )

0.00
( neutral )

-0.87
( strong negative )

PYC Therapeutics Ltd Finanse

Annual	2023
Przychody:	$15.81M
Zysk brutto:	$14.92M (94.42 %)
EPS:	$-0.00700

FY	2023
Przychody:	$15.81M
Zysk brutto:	$14.92M (94.42 %)
EPS:	$-0.00700

FY	2023
Przychody:	$0
Zysk brutto:	$0 (0.00 %)
EPS:	$0

FY	2022
Przychody:	$16.04M
Zysk brutto:	$15.20M (94.77 %)
EPS:	$-0.00430

Financial Reports:

No articles found.

PYC Therapeutics Ltd

PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of drug solutions in the areas of ribonucleic acid therapeutics in Australia. The company's preclinical development programs include VP-001, drug program for retinitis pigmentosa type 11; and PYC-001, a drug program for the treatment of autosomal dominant optic atrophy. It also focuses on the development of programs for kidney, retinal, and central nervous system diseases. PYC Therapeutics Limited has academic-industry collaborations with Murdoch University to support drug discovery and development efforts in the field of neurodegenerative disorders, including Motor Neurone Disease. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.